Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021.

Article  PubMed  PubMed Central  Google Scholar 

Commonwealth of Australia as represented by the Department of Health and Aged Care. Australian guideline for assessing and managing cardiovascular disease risk. 2023. https://www.cvdcheck.org.au/https://www.cvdcheck.org.au/. Accessed 11 Oct 2023.

Ference BA, Bhatt DL, Catapano AL, et al. Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA. 2019;322(14):1381–91.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Morton JI, Marquina C, Lloyd M, Watts GF, Zoungas S, Liew D, Ademi Z. Lipid-lowering strategies for primary prevention of coronary heart disease in the UK: a cost-effectiveness analysis. Pharmacoeconomics. 2024;42(1):91–107. https://doi.org/10.1007/s40273-023-01306-2. (PMID:37606881;PMCID:PMC10791963).

Article  PubMed  Google Scholar 

Reith C, Preiss D, Blackwell L, et al. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024;12(5):306–19.

Article  Google Scholar 

Morton JI, Liew D, Ademi Z. A causal model for primary prevention of cardiovascular disease: the health economic model for the primary prevention of cardiovascular disease. Value Health. 2024;S1098–3015(24):02791–8. https://doi.org/10.1016/j.jval.2024.07.010. (PMID: 39094690).

Article  Google Scholar 

Lotta LA, Sharp SJ, Burgess S, et al. Association between low-density Llpoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA. 2016;316(13):1383–91.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3): e1001779.

Article  PubMed  PubMed Central  Google Scholar 

Pal K, Horsfall L, Sharma M, Nazareth I, Petersen I. Time trends in the incidence of clinically diagnosed type 2 diabetes and pre-diabetes in the UK 2009–2018: a retrospective cohort study. BMJ Open Diabetes Res Care. 2021;9(1): e001989.

Article  PubMed  PubMed Central  Google Scholar 

Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349–61. https://doi.org/10.1007/s40273-015-0327-2. (PMID:26660529;PMCID:PMC4796331).

Article  PubMed  CAS  Google Scholar 

Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015;2015(3):CD008226.

A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

Gabb GM, Mangoni AA, Anderson CS, et al. Guideline for the diagnosis and management of hypertension in adults: 2016. Med J Aust. 2016;205(2):85–9.

Article  PubMed  Google Scholar 

Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet. 2018;391(10133):1897–907.

Article  PubMed  Google Scholar 

Rabin R, Oemar M, Oppe M, Janssen B, Herdman M. EQ-5D-5L user guide. Basic information on how to use the EQ-5D-5L instrument Rotterdam: EuroQol Group. 2011;22.

McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms. Health Qual Life Outcomes. 2016;14(1):133.

Article  PubMed  PubMed Central  Google Scholar 

Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes. Value Health. 2014;17(4):462–70.

Article  PubMed  Google Scholar 

Betts MB, Rane P, Bergrath E, et al. Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review. Health Qual Life Outcomes. 2020;18(1):251.

Article  PubMed  PubMed Central  Google Scholar 

Joundi RA, Adekanye J, Leung AA, et al. Health state utility values in people with stroke: a systematic review and meta-analysis. J Am Heart Assoc. 2022;11(13): e024296.

Article  PubMed  PubMed Central  Google Scholar 

Lacey EA, Musgrave RJ, Freeman JV, Tod AM, Scott P. Psychological morbidity after myocardial infarction in an area of deprivation in the UK: evaluation of a self-help package. Eur J Cardiovasc Nurs. 2004;3(3):219–24.

Article  PubMed  Google Scholar 

Australian Institute of Health and Welfare. Health expenditure Australia 2021-22. 2023. https://www.aihw.gov.au/reports/health-welfare-expenditure/health-expenditure-australia-2021-22/data. Accessed 5 Jan 2024.

Cobiac LJ, Magnus A, Barendregt JJ, Carter R, Vos T. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health. 2012;12:398.

Article  PubMed  PubMed Central  Google Scholar 

Lee CM, Colagiuri R, Magliano DJ, et al. The cost of diabetes in adults in Australia. Diabetes Res Clin Pract. 2013;99(3):385–90.

Article  PubMed  Google Scholar 

Morton JI, Marquina C, Shaw JE, Liew D, Polkinghorne KR, Ademi Z, Magliano DJ. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia. 2023;66(4):642–56. https://doi.org/10.1007/s00125-022-05832-0.PMID:36404375;PMCID:PMC9947091.

Article  PubMed  Google Scholar 

The Pharmaceutical Benefits Scheme. PBS and RPBS section 85 date of supply data. 2023. https://www.pbs.gov.au/info/statistics/dos-and-dop/dos-and-dop. Accessed 5 Jan 2024.

Edney LC, Haji Ali Afzali H, Cheng TC, Karnon J. Estimating the reference incremental cost-effectiveness ratio for the Australian health system. Pharmacoeconomics. 2018;36(2):239–52.

Department of Health. The Pharmaceutical Benefits Advisory Committee (PBAC) guidelines. https://pbac.pbs.gov.auhttps://pbac.pbs.gov.au. Accessed 28 Sept 2021

Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.

Article  PubMed  CAS  Google Scholar 

Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl.):S17-29.

Article  PubMed  Google Scholar 

Sattar N. Statins and diabetes: what are the connections? Best Pract Res Clin Endocrinol Metabol. 2023;37(3): 101749.

Article  CAS  Google Scholar 

Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. Pharmacoeconomics. 2018;36(7):745–58.

Article  PubMed  PubMed Central  Google Scholar 

Marquina C, Talic S, Vargas-Torres S, et al. Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029. Eur J Prev Cardiol. 2022;29(8):1212–9.

Article  PubMed  Google Scholar 

Abebe TB, Morton JI, Ilomaki J, Ademi Z. Future burden of myocardial infarction in Australia: impact on health outcomes between 2019 and 2038. Eur Heart J Qual Care Clin Outcomes. 2024;10(5):421–30.

Article  PubMed  Google Scholar 

Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023;148(24):1982–2004.

Article  PubMed  Google Scholar 

Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al.; Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and validation of the American Heart Association’s PREVENT Equations. Circulation. 2024;149(6):430–49. https://doi.org/10.1161/CIRCULATIONAHA.123.067626 (Erratum in: Circulation. 2024 Mar 12;149(11):e956. https://doi.org/10.1161/CIR.0000000000001230. PMID: 37947085; PMCID: PMC10910659).

Tomic D, Morton JI, Chen L, et al. Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study. Lancet Diabetes Endocrinol. 2022;10(11):795–803.

Article  PubMed  PubMed Central  Google Scholar 

Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol. 2017;186(9):1026–34.

Article  PubMed  PubMed Central  Google Scholar 

Cholesterol Treatment Trialists’ Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832–45.

Article  Google Scholar 

Hutchins R, Pignone MP, Sheridan SL, Viera AJ. Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey. BMJ Open. 2015;5(5): e006505. https://doi.org/10.1136/bmjopen-2014-006505. (PMID:2